全文获取类型
收费全文 | 8125篇 |
免费 | 581篇 |
国内免费 | 25篇 |
专业分类
耳鼻咽喉 | 62篇 |
儿科学 | 290篇 |
妇产科学 | 208篇 |
基础医学 | 1120篇 |
口腔科学 | 226篇 |
临床医学 | 854篇 |
内科学 | 1750篇 |
皮肤病学 | 111篇 |
神经病学 | 734篇 |
特种医学 | 165篇 |
外科学 | 883篇 |
综合类 | 127篇 |
一般理论 | 6篇 |
预防医学 | 931篇 |
眼科学 | 154篇 |
药学 | 579篇 |
2篇 | |
中国医学 | 37篇 |
肿瘤学 | 492篇 |
出版年
2023年 | 106篇 |
2022年 | 163篇 |
2021年 | 341篇 |
2020年 | 212篇 |
2019年 | 262篇 |
2018年 | 288篇 |
2017年 | 217篇 |
2016年 | 176篇 |
2015年 | 205篇 |
2014年 | 285篇 |
2013年 | 416篇 |
2012年 | 587篇 |
2011年 | 557篇 |
2010年 | 319篇 |
2009年 | 286篇 |
2008年 | 442篇 |
2007年 | 487篇 |
2006年 | 385篇 |
2005年 | 371篇 |
2004年 | 375篇 |
2003年 | 341篇 |
2002年 | 298篇 |
2001年 | 96篇 |
2000年 | 80篇 |
1999年 | 87篇 |
1998年 | 57篇 |
1997年 | 58篇 |
1996年 | 45篇 |
1995年 | 32篇 |
1994年 | 43篇 |
1993年 | 39篇 |
1992年 | 67篇 |
1991年 | 68篇 |
1990年 | 62篇 |
1989年 | 54篇 |
1988年 | 57篇 |
1987年 | 63篇 |
1986年 | 48篇 |
1985年 | 46篇 |
1984年 | 37篇 |
1983年 | 52篇 |
1982年 | 27篇 |
1980年 | 25篇 |
1979年 | 27篇 |
1978年 | 24篇 |
1976年 | 26篇 |
1974年 | 28篇 |
1973年 | 22篇 |
1970年 | 30篇 |
1969年 | 28篇 |
排序方式: 共有8731条查询结果,搜索用时 15 毫秒
991.
992.
993.
994.
Leslie A. Rescorla Grace Ewing Masha Y. Ivanova Marcel Aebi Niels Bilenberg Gwen C. Dieleman 《Journal of clinical child and adolescent psychology》2017,46(1):74-87
To conduct international comparisons of parent–adolescent cross-informant agreement in clinical samples, we analyzed ratings on the Child Behavior Checklist (CBCL) and Youth Self-Report (YSR) for 6,762 clinically referred adolescents ages 11–18 from 7 societies (M = 14.5 years, SD = 2.0 years; 51% boys). Using CBCL and YSR data, we asked the following questions: (a) Do parents report more problems for their adolescent children than the adolescents report about themselves? (b) How do cross-informant correlations (rs) for scale scores differ by problem type and by society? (c) How well do parents and adolescents, on average, agree regarding which problems they rate as low, medium, or high? (d) How does within-dyad item agreement vary within and between societies? (e) How do societies vary in dichotomous cross-informant agreement with respect to the deviance status of the adolescents? CBCL and YSR scores were quite similar, with small and inconsistent informant effects across societies. Cross-informant rs averaged .47 across scales and societies. On average, parents and adolescents agreed well regarding which problem items received low, medium, or high ratings (M r = .87). Mean within-dyad item agreement was moderate across all societies, but dyadic agreement varied widely within every society. In most societies, adolescent noncorroboration of parent-reported deviance was more common than parental noncorroboration of adolescent-reported deviance. Overall, somewhat better parent–adolescent agreement and more consistency in agreement patterns across diverse societies were found in these seven clinical samples than in population samples studied using the same methods. 相似文献
995.
996.
Our understanding of Alzheimer’s disease (AD) is still incomplete and, as a result, we lack effective therapies. Reprogramming to generate human-induced pluripotent stem cells provides a new approach to the generation of human neurons that carry the genomes of people with familial or sporadic AD. Differentiation of such stem cells to human neurons is already providing new insights into AD and molecular pathways that may provide new targets for effective therapy. These pathways include typical amyloid response pathways, as well as pathways leading from altered behavior of amyloid precursor protein to the elevated phosphorylation of tau protein. There is also a need for standardization of models so that isogenic lines differing only in the familial AD mutation can be compared.
Electronic supplementary material
The online version of this article (doi:10.1007/s13311-014-0326-6) contains supplementary material, which is available to authorized users. 相似文献997.
Grace O. Androga Alan M. McGovern Briony Elliott Barbara J. Chang Timothy T. Perkins Niki F. Foster Thomas V. Riley 《Journal of clinical microbiology》2015,53(3):973-975
Clostridium difficile PCR ribotype 033 (RT033) is found in the gastrointestinal tracts of production animals and, occasionally, humans. The illumigene C. difficile assay (Meridian Bioscience, Inc.) failed to detect any of 52 C. difficile RT033 isolates, while all strains signaled positive for the binary toxin genes but were reported as negative for C. difficile by the Xpert C. difficile/Epi assay (Cepheid). 相似文献
998.
Shin-Heng Chiou Ian P. Winters Jing Wang Santiago Naranjo Crissy Dudgeon Fiona B. Tamburini Jennifer J. Brady Dian Yang Barbara M. Grüner Chen-Hua Chuang Deborah R. Caswell Hong Zeng Pauline Chu Grace E. Kim Darren R. Carpizo Seung K. Kim Monte M. Winslow 《Genes & development》2015,29(14):1576-1585
Pancreatic ductal adenocarcinoma (PDAC) is a genomically diverse, prevalent, and almost invariably fatal malignancy. Although conventional genetically engineered mouse models of human PDAC have been instrumental in understanding pancreatic cancer development, these models are much too labor-intensive, expensive, and slow to perform the extensive molecular analyses needed to adequately understand this disease. Here we demonstrate that retrograde pancreatic ductal injection of either adenoviral-Cre or lentiviral-Cre vectors allows titratable initiation of pancreatic neoplasias that progress into invasive and metastatic PDAC. To enable in vivo CRISPR/Cas9-mediated gene inactivation in the pancreas, we generated a Cre-regulated Cas9 allele and lentiviral vectors that express Cre and a single-guide RNA. CRISPR-mediated targeting of Lkb1 in combination with oncogenic Kras expression led to selection for inactivating genomic alterations, absence of Lkb1 protein, and rapid tumor growth that phenocopied Cre-mediated genetic deletion of Lkb1. This method will transform our ability to rapidly interrogate gene function during the development of this recalcitrant cancer. 相似文献
999.
Grace Liu Joel Segrè A Metin Gülmezoglu Matthews Mathai Jeffrey M Smith Jorge Hermida Aline Simen-Kapeu Pierre Barker Mercy Jere Edward Moses Sarah G Moxon Kim E Dickson Joy E Lawn Fernando Althabe Working Group for the UN Commission of Life Saving Commodities Antenatal Corticosteroids 《BMC pregnancy and childbirth》2015,15(Z2):S3
Background
Preterm birth complications are the leading cause of deaths for children under five years. Antenatal corticosteroids (ACS) are effective at reducing mortality and serious morbidity amongst infants born at <34 weeks gestation. WHO guidelines strongly recommend use of ACS for women at risk of imminent preterm birth where gestational age, imminent preterm birth, and risk of maternal infection can be assessed, and appropriate maternal/newborn care provided. However, coverage remains low in high-burden countries for reasons not previously systematically investigated.Methods
The bottleneck analysis tool was applied in 12 countries in Africa and Asia as part of the Every Newborn Action Plan process. Country workshops involved technical experts to complete the survey tool, which is designed to synthesise and grade health system "bottlenecks", factors that hinder the scale up, of maternal-newborn intervention packages. We used quantitative and qualitative methods to analyse the bottleneck data, combined with literature review, to present priority bottlenecks and actions relevant to different health system building blocks for ACS.Results
Eleven out of twelve countries provided data in response to the ACS questionnaire. Health system building blocks most frequently reported as having significant or very major bottlenecks were health information systems (11 countries), essential medical products and technologies (9 out of 11 countries) and health service delivery (9 out of 11 countries). Bottlenecks included absence of coverage data, poor gestational age metrics, lack of national essential medicines listing, discrepancies between prescribing authority and provider cadres managing care, delays due to referral, and lack of supervision, mentoring and quality improvement systems.Conclusions
Analysis centred on health system building blocks in which 9 or more countries (>75%) reported very major or significant bottlenecks. Health information systems should include improved gestational age assessment and track ACS coverage, use and outcomes. Better health service delivery requires clarified policy assigning roles by level of care and cadre of provider, dependent on capability to assess gestational age and risk of preterm birth, and the implementation of guidelines with adequate supervision, mentoring and quality improvement systems, including audit and feedback. National essential medicines lists should include dexamethasone for antenatal use, and dexamethasone should be integrated into supply logistics.1000.
The incidence and management of infusion reactions to infliximab: a large center experience 总被引:8,自引:0,他引:8
Cheifetz A Smedley M Martin S Reiter M Leone G Mayer L Plevy S 《The American journal of gastroenterology》2003,98(6):1315-1324
OBJECTIVE: To assess the incidence and management of infusion reactions to infliximab, a chimeric monoclonal antibody that targets human tumor necrosis factor-alpha, in patients with Crohn's disease treated at a large infusion center. METHODS: A total of 165 consecutive patients who received 479 infliximab infusions in the Division of Clinical Immunology Infusion Center at Mount Sinai Medical Center from July, 1998 to January, 2001 were evaluated. Specific treatment protocols for initial and subsequent acute infusion reactions were followed and the outcomes documented. RESULTS: The overall incidence of infusion reactions to infliximab was 6.1% (29 of 479) of infusions, affecting 9.7% (16 of 165) of patients. Mild, moderate, or severe acute reactions occurred in 3.1% (15 of 479), 1.2% (six of 479), and 1.0% (five of 479) of infliximab infusions, respectively. Use of treatment protocols resulted in rapid resolution of all acute reactions to infliximab. With the prophylaxis protocol, all patients who experienced an initial mild or moderate acute reaction were able to receive additional infusions. Four patients experienced a total of five severe acute reactions. Three patients were retreated: two patients had no further problems, whereas one patient had a second severe acute reaction that rapidly resolved with treatment. Suggesting that acute infusion reactions are not type I hypersensitivity reactions, in 11 patients who experienced 14 acute infusion reactions, serum tryptase levels were normal. Delayed infusion reactions occurred in 0.6% (three of 479) of infusions. CONCLUSIONS: Infliximab infusions were accompanied by acute reactions in approximately 5% of infusions. These reactions did not seem to be true IgE-mediated type I hypersensitivity events. Using appropriate treatment protocols, these reactions were effectively treated and prevented upon retreatment in nearly all patients. Delayed reactions were rare, occurring in <1% of infusions. 相似文献